Angela B. Smith, MD, MS, stresses that balancing PROs with traditional clinical end points begins with engaging patients early in the trial design process.
Angela B. Smith, MD, MS
Advertisement
Smith is vice chair of Academic Affairs and a professor of urology at the University of North Carolina School of Medicine, Chapel Hill.
Articles by Angela B. Smith, MD, MS
The findings revealed that patients prioritized improvements in overall survival and reductions in cancer recurrence at 5 years over all other treatment factors
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves first-line Zenflow system for the treatment of BPH
2
Experts urge FDA to revisit labeling for testosterone replacement therapy in men
3
FDA approves gepotidacin for uncomplicated urogenital gonorrhea
4
Mohit Khera, MD, recaps key takeaways from FDA panel on TRT for men
5
